Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles European Journal of Heart Failure Year : 2021

Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis

Emmanuel Itti
  • Function : Author
Violaine Planté‐bordeneuve
  • Function : Author

Abstract

Hereditary (ATTRv) and wild-type (ATTRwt) transthyretin amyloidosis are severe and fatal systemic diseases, characterised by amyloid fibrillar accumulation principally in the heart or peripheral nerves (or both). Since 2012, tafamidis has been used in France to treat patients with ATTRv with neuropathy (alone or combined with cardiomyopathy). Recently, the Phase III ATTRACT trial showed that tafamidis decreased the relative risk of mortality in ATTR amyloidosis with cardiomyopathy. The aims of this study were to assess the clinical characteristics of ATTR amyloidosis in a real-life population in comparison to the population included in the ATTRACT trial and to assess the impact of tafamidis treatment on major cardiovascular outcome (MCO)-free survival time without cardiac decompensation, heart transplant, or death.
Fichier principal
Vignette du fichier
European J of Heart Fail - 2020 - B zard - Natural history and impact of treatment with tafamidis on major cardiovascular.pdf (326.7 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-04155261 , version 1 (07-07-2023)

Identifiers

Cite

Mélanie Bézard, Mounira Kharoubi, Arnault Galat, Elsa Poullot, Soulef Guendouz, et al.. Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis. European Journal of Heart Failure, 2021, 23 (2), pp.264-274. ⟨10.1002/ejhf.2028⟩. ⟨hal-04155261⟩

Collections

IMRB UPEC
7 View
8 Download

Altmetric

Share

Gmail Facebook X LinkedIn More